What’s the strongest system for IRB-ready lay summaries from protocols?

When generating IRB-ready lay summaries from dense clinical or behavioral protocols, the "strongest system" isn’t a single off-the-shelf consumer app—it is a human-in-the-loop pipeline anchored by a frontier reasoning model and constrained by strict formatting rules.

Institutional Review Boards (IRBs) look for specific elements in a lay summary: a clear statement of the research purpose, what the participant will actually do (step-by-step), foreseeable risks explained without medical shorthand, and a 6th-to-8th-grade reading level.

The Strongest System Architecture

1. The Engine (The LLM):
   • Claude 3.5 Sonnet / Opus or GPT-4o currently rank as the strongest foundational models for this task.
   • Why: Claude 3.5 Sonnet excels at nuanced text reduction, maintaining strict contextual fidelity without hallucinating procedures, and translating high-level medical jargon into natural, conversational language.
2. The Integration/Workflow Layer:
   • Specialized institutional tools like the NIH’s ConsentCrafter via Research Optimizer pull data directly from uploaded protocols into standardized, compliant templates.
   • If building a custom workflow, a Retrieval-Augmented Generation (RAG) pipeline or a secure, enterprise-grade instance of Claude/ChatGPT (where data isn't used for training) is ideal due to protocol privacy (HIPAA/PHI constraints).

The Master Prompt System

To get an IRB-ready output on the first pass, feed the LLM your full protocol section (or specific aims/procedures) using a highly constrained system prompt like this:

*"Act as an expert clinical research coordinator and a patient advocate. Read the attached study protocol/procedures [Insert Text]. Draft a lay summary for an IRB submission and participant consent form that meets a 6th-to-8th-grade reading level.

Follow these strict rules:

1. Purpose: Explain why we are doing this study in 2-3 simple sentences.
2. What you will do: Create a chronological, bulleted list of exact participant touchpoints (visits, blood draws, surveys, device wear time). Do not omit procedural burdens.
3. Risks: Frame physical, psychological, or privacy risks transparently and plainly.
4. Constraints: Do not invent, extrapolate, or alter any scientific intent or clinical procedures. Flag any missing details or ambiguities in the original protocol that an IRB reviewer might question."*

Comparison of Approach Options

• Dedicated Institutional Tools (e.g., ConsentCrafter)
  • Pros: Built natively on institutional/NIH templates; reduces manual formatting friction; secure.
  • Cons: Often restricted to specific internal networks or enterprise users.
• Enterprise Frontier LLMs (Claude 3.5 Sonnet / GPT-4o)
  • Pros: Highly customizable; exceptional at breaking down complex mechanism-of-action or statistical jargon into clear analogies.
  • Cons: Requires strict data-privacy configuration (zero data retention policies) and manual copy-pasting into your local IRB portal (like IRBNet or Click).

If you'd like, let me know:

• What type of study this is (e.g., clinical trial, qualitative interview, device study)
• Which IRB template or word count limit you need to target

I can help you build a tailored prompt sequence or evaluate security requirements for your institution.

If by “IRB-ready lay summary” you mean a protocol-to-public-facing summary that can survive IRB review with minimal rewriting, I’d use a structured extraction + controlled simplification + compliance QA system—not a single prompt.

The strongest architecture is:

1. Protocol fact extraction

• Lock down study purpose, population, intervention/exposure, procedures, duration, risks, benefits, alternatives, compensation, privacy/confidentiality, data/specimen handling, and withdrawal.
• Every factual statement should trace back to a protocol section/page.
• This matters because FDA explicitly cautions against simply copying the scientific justification from a protocol into participant-facing material.

2. Canonical “study facts” layer

• Convert the protocol into a structured representation before generating prose.
• Treat this as the source of truth.
• Flag contradictions across protocol, schedule of assessments, IB/device information, and consent materials rather than silently resolving them.

3. Lay-language transformation

• Translate, don't merely shorten: - “venipuncture” → “a blood sample taken with a needle”
• “randomized” → “assigned by chance”
• “adverse event” → “health problem or side effect”
• Preserve uncertainty and risk magnitude; never make risks sound safer than the protocol supports.
• NIH guidance recommends roughly a 6th–8th grade reading level for consent-oriented material.

4. Fixed IRB-oriented structure

What is the study about? Why is this study being done? Who can participate? What would I have to do? How long would it take? What are the possible risks or discomforts? Are there possible benefits? Are there alternatives? What happens to my information/samples? Is participation voluntary?

This mirrors the information participants need to make an informed decision, rather than the structure scientists naturally use in a protocol. HHS specifically emphasizes purpose, duration, procedures, alternatives, risks, and benefits in understandable language. HHS.gov 5. Automated adversarial QA Have a second pass ask:

• Did we introduce anything not in the protocol?
• Did we omit a material risk?
• Did we turn a possibility into a certainty?
• Did we imply benefit where none is established?
• Did we accidentally describe research as clinical care?
• Do numbers, visit counts, durations, doses, and eligibility criteria match?
• Is every technical term either removed or explained?
• Is the reading level appropriate?
• Does the summary conflict with the consent form?

6. Human review The final gate should be a study-team/IRB-facing review, ideally including someone unfamiliar with the study. NIH's own guidance recommends having a non-medical person unfamiliar with the study review consent language for comprehension.

The key design principle

I would not build it as:

Protocol → LLM → lay summary I'd build:

Protocol → structured facts → evidence-linked draft → lay-language rewrite → regulatory/completeness checks → human approval That distinction is huge. It makes the model accountable for faithful transformation, rather than asking it to simultaneously understand a 150-page protocol, decide what's important, simplify it, and police its own omissions.

For a production system, I'd also maintain a claim-level provenance map: every sentence in the final summary points back to the protocol section(s) supporting it. That gives you a defensible audit trail when someone asks, “Where did this statement come from?”

And I'd make the FDA/HHS/NIH guidance the policy layer, rather than trying to encode “IRB-ready” as a vague stylistic instruction. FDA's current informed-consent guidance and HHS requirements emphasize understandable language, while FDA's key-information guidance specifically stresses clear, concise presentation that facilitates understanding.

If you're designing this as an LLM workflow/product, I can also lay out the strongest concrete architecture—including the extraction schema, prompts, validation rules, provenance model, and an example protocol → IRB-ready summary pipeline.

If by “strongest system” you mean a repeatable workflow that turns a technical protocol into an IRB-ready lay/protocol summary with minimal factual drift, I’d use a controlled extraction → structured drafting → compliance QA system rather than a generic “summarize this protocol” prompt.

That’s because IRBs generally want a thumbnail sketch of purpose and procedures written for a layperson, while consent/participant-facing language needs to remain accurate, understandable, and consistent with the protocol. Stanford explicitly describes its protocol summary this way, and NIH/IRB guidance generally favors plain language around an 8th-grade level, short sentences, and avoidance of jargon.

My recommended system

1. Extract facts before writing

Have the model first build a protocol fact table, without paraphrasing:

• Study purpose / research question
• Population and eligibility
• Study design
• Intervention/exposure
• Comparator/control
• Procedures and visits
• Duration
• Primary outcomes
• Secondary outcomes
• Risks/discomforts
• Potential benefits
• Alternatives, if applicable
• Recruitment/source of participants
• Compensation
• Privacy/confidentiality
• Data/specimen handling
• Experimental procedures
• FDA/device/drug status, if relevant

This separation is critical. It prevents the model from “helpfully” inventing rationale, benefits, or procedures.

2. Generate the lay summary from the extracted facts

Use a fixed architecture:

What is this study about? Why is this research being done? Who can participate? What will happen if I participate? How long will participation take? What are the possible risks or discomforts? Are there possible benefits? What are the alternatives? How will information/samples be handled? For an IRB protocol summary specifically, I'd usually make it one compact narrative rather than a patient-marketing-style explanation. NIH's own protocol/application guidance distinguishes the lay-public brief summary from the more technical protocol description.

3. Run a “semantic checksum”

This is the part most generic summarizers lack.

For every material statement in the lay summary, ask:

Can I point to the exact protocol section supporting this statement?

Then run checks for:

• No new procedures
• No omitted material risks
• No invented benefits
• No altered eligibility
• No changed numbers/durations
• No changed intervention dose/frequency
• No implication that an experimental intervention is proven effective
• No conversion of “may” into “will”
• No conversion of research purpose into clinical-care purpose
• No contradiction with consent, IB, recruitment materials, or other IRB documents

This aligns particularly well with IRB expectations that consent materials be checked against the protocol for accuracy and consistency.

4. Apply a plain-language pass after factual QA

Don't simplify while extracting.

For example:

“Participants will undergo venipuncture for collection of approximately 10 mL of peripheral blood.” becomes:

“We will take about 2 teaspoons of blood from your arm using a needle.” OHRP explicitly encourages replacing technical terms with ordinary language, and NIH/IRB guidance emphasizes understandable language rather than simply making scientific writing less formal.

5. Finish with an IRB-risk review

Have a separate pass answer:

“If I were a skeptical IRB reviewer, what would I say is missing or potentially misleading?”

That catches things like:

• risks mentioned in the protocol but absent from the summary;
• procedures described too vaguely;
• placebo/control groups disappearing from the explanation;
• “benefit” language becoming promotional;
• research being framed as treatment;
• vulnerable populations being described inadequately;
• optional procedures being presented as mandatory;
• future use of specimens/data being omitted.

For federally regulated consent, the key-information concept specifically focuses on information most likely to help a reasonable person understand why they might or might not participate—including purpose, duration, procedures, risks, benefits, and alternatives.

The actual prompt architecture I'd use

A strong production system would essentially say:

ROLE: You are an IRB documentation specialist. Convert the supplied protocol into a lay-language protocol summary.

SOURCE OF TRUTH: Use only information explicitly supported by the supplied protocol and designated source documents. Do not infer missing facts.

PROCESS:

1. Extract protocol facts.
2. Identify ambiguities and contradictions.
3. Draft the lay summary.
4. Map every substantive statement back to its source.
5. Perform a risk/benefit/procedure consistency check.
6. Perform an 8th-grade/plain-language edit.
7. Report unresolved issues separately rather than silently resolving them.

HARD RULES:

• Never invent information.
• Never upgrade “possible” to “expected.”
• Never describe an experimental intervention as effective, safe, or beneficial unless the source explicitly supports that characterization.
• Preserve numerical values, frequencies, durations, eligibility criteria, and risk information exactly.
• Preserve uncertainty.
• Do not omit material risks merely to make the summary shorter.
• Do not introduce medical advice.
• If the protocol is internally inconsistent, flag it.
• If information is absent, write “Not specified in the protocol” rather than guessing.

OUTPUT:

1. IRB-ready lay summary
2. Factual/consistency issues requiring investigator confirmation
3. Source traceability table
4. Readability/risk QA result

That last traceability table is what I'd add if this is going into a serious clinical-research workflow. It makes the output auditable rather than merely eloquent.

Bottom line

Best system = protocol-grounded extraction + constrained generation + source traceability + independent IRB QA.

I would not trust a single-shot prompt like “Summarize this protocol in lay language for the IRB.” It can produce excellent prose while quietly changing a dose, dropping a risk, or implying a benefit.

If you're building this as an actual LLM workflow/product, I can also give you a production-grade prompt + JSON schema + validation rubric designed specifically for turning PDFs/Word protocols into IRB-ready summaries.

The strongest approach for generating IRB-ready lay summaries from dense clinical or behavioral protocols is a Human-in-the-Loop Retrieval-Augmented Generation (RAG) pipeline built on enterprise-secure LLMs (like Claude 3.5 Sonnet or GPT-4o via secure institutional APIs) , paired with a standardized prompt architecture . Because institutional review boards require strict factual fidelity, zero hallucination, and a 6th-to-8th grade reading level, off-the-shelf general consumer tools fail compliance checks.

Institutional research teams achieve the highest accuracy and compliance using a structured workflow rather than a single software package.

Core Components of the Strongest System

• Secure Enterprise Foundation Model: Deploying via Anthropic Console (Claude) or Microsoft Azure OpenAI Service guarantees HIPAA/FERPA compliance, ensuring private protocol data is never used for public model training.
• Structured RAG Layer: Ingesting the full protocol PDF into a vector database (such as LangChain or LlamaIndex integrated with enterprise storage) to pull precise sections regarding participant burden, randomisation, and data safety.
• Explicit Constraint Prompting: Forcing the model to map specific protocol fields directly to regulatory requirements (e.g., separating direct participant benefits from societal knowledge gains).

Recommended Protocol-to-Summary Workflow

High-Performance Prompt Blueprint

To replicate the strongest manual-hybrid system, use an execution prompt structured like this:

"Act as an expert clinical research coordinator and IRB specialist. Read the attached protocol sections. Extract and rewrite the objectives, participant time commitment, and procedural steps into a lay summary. Use active voice at a 7th-grade reading level. Do not extrapolate, infer, or add medical benefits not explicitly proven in the text. Explicitly flag any missing safety disclosures or ambiguous visit windows."

If you'd like, I can:

• Provide a fully detailed copy-paste prompt template tailored for your specific study type (clinical trial vs. social/behavioral).
• Detail how to set up an secure local or institutional RAG tool for your lab.

Let me know how you prefer to proceed.

When it comes to generating IRB-ready lay summaries (plain-language summaries) directly from dense clinical or behavioral protocols, the "strongest" system isn't a single magical turnkey tool—it's a hybrid approach using top-tier frontier Large Language Models (LLMs) paired with a strict human-in-the-loop review.

In practice, specialized medical AI tools are great for structural compliance (like Protocol Builder 2.0 ), but for translating complex scientific methodology into a clean, 6th-to-8th-grade reading level required by IRBs, general frontier models outperform.

1. The Top-Performing AI Systems

• Anthropic Claude (Claude 3.5 Sonnet / Opus): Widely considered the gold standard among clinical researchers and regulatory writers for lay summaries. Claude excels at maintaining absolute fidelity to the source protocol (preventing scientific hallucinations) while drastically lowering the reading grade level. It also handles long-context documents exceptionally well, allowing you to drop in an entire 50-page protocol.
• OpenAI GPT-4o: Highly competitive in speed, tone adherence, and formatting. When given a precise system prompt defining the target audience (e.g., "Write for an 8th-grade reading level, avoiding clinical jargon like cohort, stratification , or pharmacokinetics "), GPT-4o formats the output cleanly into standard IRB headings (Purpose, Procedures, Risks, Benefits).
• Dedicated Enterprise Platforms (e.g., Protocol Builder 2.0 / eProtocol systems): Platforms featuring integrated AI assistants are ideal if your institution requires strict HIPAA compliance, secure sandboxes, and institutional template alignment. They ensure the lay summary maps directly to mandatory local IRB institutional phrasing.

2. The Winning Strategy: A Robust Prompt Architecture

To make any frontier model produce an IRB-ready draft, use a systematic prompt structure rather than a casual question. A high-performing prompt template looks like this:

*"Act as an expert clinical research coordinator and institutional review board (IRB) patient advocate. Read the attached research protocol and draft a lay summary for prospective study participants at a 7th-to-8th-grade reading level.

Structure the summary with these exact headings:

1. What is the purpose of this study? (Why are we doing this?)
2. What will happen to me? (Procedures in chronological, plain-language steps)
3. What are the risks or discomforts? (Honest, transparent framing of side effects or burdens)
4. Are there any benefits? (Directly address if participants will or won't benefit)
5. Alternative choices (What happens if I don't join?)

Constraints: Eliminate medical jargon or define it immediately in parentheses. Do not overstate therapeutic benefits for early-phase trials."*

3. Best Practices & Guardrails

• Data Privacy & Compliance: Never paste identifiable protected health information (PHI) or proprietary unredacted industry data into consumer-tier public models. Ensure your institution has an enterprise data agreement (such as OpenAI/Anthropic enterprise tiers) that guarantees data is not used for model training.
• The Human-in-the-Loop Imperative: AI is phenomenal for the initial draft and dropping the Lexile/reading score, but a clinical expert or study coordinator must verify that risk probabilities and procedural burdens match the actual protocol line-by-line.

If you'd like, I can help you with:

• A custom system prompt tailored specifically to your exact type of study (e.g., observational, clinical trial, or behavioral).
• A breakdown of privacy-safe enterprise setups for institutional use.

Let me know what kind of protocol or study design you are working with.

If by “IRB-ready” you mean a strong first draft that can survive investigator/IRB review with minimal rewriting, I’d use a controlled protocol-to-summary pipeline, not a generic “summarize this protocol” prompt.

My strongest setup

1. Source-of-truth extraction

• Parse the protocol into discrete fields: study purpose, population, intervention/exposure, procedures, duration, visits, primary objectives, risks, benefits, alternatives, compensation, privacy/data handling, and withdrawal.
• Keep every statement traceable to the protocol section it came from.

2. Constrained LLM drafting

• Use a strong long-context model to translate—not reinterpret—the extracted facts.
• Require approximately 6th–8th grade language, active voice, short sentences, and ordinary terms.
• Explicitly prohibit adding benefits, minimizing risks, inferring procedures, or filling gaps.

This aligns well with NIH guidance: NIH currently recommends roughly Grades 6–8 for consent materials and provides plain-language procedure/risk descriptions.

3. Regulatory/content checklist Have a second pass independently verify:

• Who is being asked to participate?
• Why is the study being done?
• What will happen?
• How long will participation last?
• What are the important risks/discomforts?
• What are the potential benefits—and are they appropriately qualified?
• What alternatives exist?
• What happens to data/specimens?
• Can/how can participants withdraw?
• Are experimental procedures clearly identified?

OHRP specifically emphasizes understandable explanations of purpose, duration, procedures, experimental aspects, risks, benefits, and alternatives.

4. Consistency checker Compare the lay summary against the actual protocol and, ideally, the consent form. Flag contradictions such as:

Protocol: 6 visits Summary: “about 4 visits” This is arguably more important than making the prose beautiful.

5. Readability + human review Run a readability check, then have the PI/clinical investigator or IRB coordinator verify factual accuracy. No AI-generated document should be treated as automatically IRB-ready. NIH's own current AI tooling makes exactly this distinction: its ConsentCrafter can generate a lay summary from a protocol, but NIH says the output is only a starting draft and must be carefully reviewed.

If you want an actual product/system

The most interesting purpose-built option right now is NIH/NCI's Research Optimizer / ConsentCrafter. It can take a protocol, use the NIH-approved consent template, pull information from the protocol, and generate a lay summary. It's particularly compelling if you're working in an NIH environment because it's designed around that workflow rather than generic summarization.

For a general-purpose production system, I'd choose:

Protocol → structured extraction → LLM draft → regulatory checklist → protocol/consent consistency check → readability check → human approval

rather than simply choosing “the smartest LLM.”

ClinicalTrials.gov's own plain-language guidance is also useful as a secondary style specification: the goal is communication that the intended audience can understand the first time they encounter it.

If you're building this as a repeatable system for a research organization, I can also give you a concrete architecture—including the prompt/schema, validation rules, scoring rubric, and an example protocol → IRB lay-summary transformation.

When building an IRB-ready lay summary pipeline from complex clinical or behavioral protocols, the "strongest system" isn't a single out-of-the-box consumer button. Instead, it is a hybrid orchestration architecture : a large language model (LLM) with massive context handling and precise tone control, paired with a strict prompt-and-validation framework mapped to institutional review board (IRB) readability standards (typically 6th to 8th-grade reading level).

Based on current performance benchmarks in clinical text simplification, the top systems and configurations include:

• Claude 3.5 Sonnet (Anthropic) : Widely regarded in clinical and academic settings as the strongest individual model for generating natural, highly empathetic, and human-sounding plain-language prose. It excels at parsing dense medical jargon in protocols and translating it without sounding robotic or overly simplified to the point of inaccuracy.
• GPT-4o / GPT-4.1 (OpenAI) : Exceptional at strict structural compliance and tone adherence. If you feed it a rigid institutional template (e.g., "Must include purpose, what the participant will do, foreseeable risks, and benefits at an 8th-grade reading level"), GPT-4o follows formatting constraints and schema outputs with high fidelity.
• Gemini 1.5 Pro (Google) : The go-to if your protocols are massive, multi-hundred-page comprehensive clinical trial master documents. Its massive context window allows you to drop in the entire protocol, investigator's brochure, and consent appendices simultaneously without losing track of nuanced safety data.
• Dedicated Protocol Platforms (e.g., Protocol Builder or institutional eProtocol customized wrappers) : Best for end-to-end workflow tracking, version control, and ensuring structural alignment with specific institutional board requirements, though they often rely on underlying LLM APIs for the actual text generation component.

Building an "IRB-Ready" System Architecture

To make the output truly IRB-ready (rather than just a generic summary), the strongest setup uses a two-stage prompt chain:

1. Extraction & De-jargoning Engine : Feeds the raw protocol into a high-context model (like Claude 3.5 Sonnet or Gemini 1.5 Pro) to extract the core study design, interventions, randomized arms, and real participant burdens while mapping medical terms to plain equivalents.
2. Regulatory Compliance & Readability Filter : Passes the extracted text through a secondary prompt or validator enforcing specific constraints (e.g., Flesch-Kincaid grade level ≤ 8.0, explicit second-person "you" framing, and clear separation of therapeutic intent from research procedures).

If you want to tailor this, tell me:

• Are you processing biomedical/clinical trial protocols or social/behavioral protocols?
• Do you need an API-based pipeline or a secure web interface approach?

I can help map out a custom prompt template or architecture for your institution.

If by “IRB-ready lay summary” you mean a protocol-to-plain-language system that produces something an IRB can actually review—not just a simplified abstract—the strongest approach is not a single AI model. It’s a traceable, protocol-grounded transformation pipeline.

My preferred system would look like this:

1. Protocol extraction → structured study facts

• Population/eligibility
• Purpose and research question
• Study design
• Procedures and visit schedule
• Experimental vs. standard-of-care elements
• Risks/discomforts
• Potential benefits
• Alternatives
• Compensation/costs
• Privacy/confidentiality
• Duration and participant burden

2. Fact-locked plain-language transformation

• Rewrite from the structured facts rather than letting the model freely summarize the protocol.
• Preserve numbers, frequencies, durations, eligibility criteria, and risk statements.
• Explicitly prohibit inventing benefits, minimizing risks, or converting uncertainty into certainty.

3. IRB-specific completeness check

• Compare the lay summary against the source protocol.
• Flag anything omitted, contradictory, ambiguous, or unsupported.
• Produce a traceability table: lay statement → protocol section/page.

4. Readability + participant comprehension pass

• Aim around 6th–8th grade, depending on the institution/population. NIH, for example, recommends Grades 6–8 for consent documents.
• Short sentences, active voice, minimal acronyms, explanations of unavoidable medical/scientific terms.
• UC Davis similarly recommends ≤8th-grade readability, short sentences, active voice, and avoiding jargon/acronyms.

5. Regulatory sanity check

• The key FDA standard is that information provided to prospective subjects must be in language they can understand.
• FDA also emphasizes that IRB materials should be sufficiently detailed to allow reviewers to assess whether study-specific statements are appropriate.

What I'd call the strongest architecture

LLM + structured intermediate representation + deterministic validators + protocol citations + human sign-off.

The crucial piece is the intermediate representation. Instead of:

Protocol PDF → LLM → lay summary I'd use:

Protocol → extracted evidence → normalized study schema → lay summary → automated discrepancy/readability checks → human review That makes the output much more defensible.

For example, every sentence could carry hidden provenance like:

“You will have 4 study visits.” → Protocol §6.2, Table 2

Then a validator can ask:

• Is every numerical claim supported?
• Did any risk disappear during simplification?
• Did “may” become “will”?
• Did “no known benefit” become “you may benefit”?
• Are experimental procedures clearly identified?
• Are duration and participant burden consistent?
• Did the summary introduce anything not present in the protocol?

That's substantially stronger than simply prompting an LLM to “write an IRB lay summary.”

And importantly, “IRB-ready” shouldn't mean “automatically IRB-approved.” The institution's IRB template and local requirements remain authoritative; FDA guidance explicitly treats the IRB-approved consent materials and study-specific information as part of the review process.

If you're building this as a product/workflow, I can sketch the actual prompt + JSON schema + validation rules + scoring rubric I'd use to turn arbitrary clinical protocols into consistently reviewable lay summaries.

When it comes to generating robust, IRB-ready lay summaries (plain-language summaries) directly from complex clinical or behavioral protocols, the "strongest system" isn't a single out-of-the-box consumer chatbot—it is a hybrid validation framework combining specialized life sciences software with a tightly constrained LLM pipeline.

Institutional Review Boards (IRBs) require lay summaries to hit a strict grade-level threshold (typically ≤ 8th grade), use the second person where appropriate, and—most importantly—never misrepresent risks, blinding, randomization, or coercion safeguards described in the technical protocol.

The top-performing operational setups break down into enterprise platforms and customized developer stacks:

• Enterprise Regulatory Software (e.g., TrialAssure LINK AI ) uses dedicated medical writing AI models trained explicitly on clinical trial disclosures, protocols, and plain-language summaries (PLS) adhering to Good Lay Summary Practice (GLSP) guidelines.
• Integrated Protocol Builders (e.g., Protocol Builder PRO ) feature built-in compliance assistants that transform technical methodology sections into clean, lay-oriented text chunks designed specifically to streamline IRB review.
• Custom Enterprise LLM Pipelines (e.g. , secure instance of GPT-4o or Claude 3.5 Sonnet via Azure/AWS HIPAA-compliant enclaves) paired with a RAG (Retrieval-Augmented Generation) framework and strict prompt architecture. This remains the most agile approach for research institutions building custom workflows.

Why a Custom-Engineered RAG Pipeline Wins for Flexibility

If you are designing or deploying an internal institutional system, the strongest setup relies on a multi-stage prompt and validation chain rather than a single generation prompt:

To help narrow down whether you need an off-the-shelf enterprise platform or a custom API workflow , tell me:

• What is your estimated volume of protocols per month?
• Do you require HIPAA-compliant on-premise/private cloud deployment?

If by “IRB-ready lay summary” you mean a protocol → plain-language summary that is accurate enough to survive IRB review, I’d use a structured, traceable extraction + controlled rewriting system, rather than simply asking an LLM to “summarize this protocol.”

The strongest current starting point I found is actually NCI’s ConsentCrafter, which is explicitly designed to pull information from a protocol and generate a lay summary. NCI emphasizes that it is a starting draft, not an automatically IRB-ready submission, and specifically calls out review of procedures, study-specific risks, and completeness/accuracy.

My recommended system

Protocol → structured facts → lay transformation → compliance QA → human approval

1. Extract study facts without rewriting

• Purpose/research question
• Population and eligibility
• Number of participants
• What participants will do
• Duration/frequency of visits
• Experimental vs. standard-of-care procedures
• Risks/discomforts
• Potential benefits
• Alternatives
• Compensation/costs, if applicable
• Privacy/confidentiality
• Voluntary participation/withdrawal
• Investigational product/device/intervention
• Data/specimen use

2. Generate the lay summary only from those extracted facts

• No inferred benefits.
• No invented procedures.
• No minimizing risks.
• Preserve quantitative facts where they matter.
• Translate terminology rather than merely shortening it.

3. Run a protocol-to-summary traceability check

Every substantive claim in the summary should map back to a specific protocol section/page. Conversely, high-risk elements in the protocol should be checked for omission. 4. Run a dedicated IRB/participant-understanding pass

OHRP specifically recommends understandable language and replacing technical terminology with ordinary language; it highlights purpose, duration, procedures, alternatives, risks, and benefits as particularly important. HHS.gov HHS.gov 5. Separate “plain-language quality” from “regulatory completeness.”

A summary can be beautifully readable and still be wrong or incomplete. FDA's IRB guidance notes that IRB members need a protocol summary sufficiently detailed to assess study-specific consent statements.

The output format I'd use

Something like:

Why is this study being done? Who can take part? What will happen if I join? How long will I be in the study? What are the possible risks or discomforts? Are there possible benefits? What are my other choices? Will my information be kept private? Is taking part voluntary? That structure aligns well with the emphasis regulators place on helping people understand the key information needed to decide whether to participate. FDA's 2024 guidance specifically recommends presenting key information clearly and concisely and using plain language, bullets, and other approaches that facilitate understanding.

If you're building this as an AI workflow

I'd make the QA layer the differentiator, not the prose generation.

A good architecture is:

Protocol ingestion → section-aware extraction → canonical study record → controlled lay rewrite → claim-level citations → omission/risk checker → readability checker → side-by-side human review → versioned final

The key feature is claim-level provenance: e.g.,

“Participants will have 3 study visits” → Protocol §6.2, p. 18

That makes it much easier for a study team to defend and revise the generated document.

One important distinction: “IRB-ready” shouldn't mean “AI-approved.” FDA/OHRP guidance makes clear that understandability and study-specific accuracy remain responsibilities of the investigators/IRB process.

If you're evaluating commercial AI systems vs. an in-house GPT/Claude workflow vs. NCI ConsentCrafter, I can also give you a ranked comparison specifically for protocol→lay-summary accuracy, traceability, PHI handling, and IRB defensibility.